In our study, we have demonstrated that serum levels of IL-6 before the intravenous thrombolysis were lower in the subgroup of patients with a favourable functional outcome compared to the group of patients with an unfavourable functional result (mRS: 3–6 pts) assessed on admission, on discharge, after 3 months and after a year since the stroke. This evidence concerns the gene IL6 and stroke disorder.